All PlansCoverageMedium impact
Recall: Dabigatran
UPMC Health Plan·Cardiology, Internal Medicine, Family Medicine +1 more·Pharmacy
Effective date
Apr 4, 2023
We identified it
Aug 7, 2026
Summary
Ascend Laboratories LLC has recalled 10 lots of Dabigatran capsules due to contamination with N-nitroso-dabigatran above acceptable levels. This is a pharmacy safety recall affecting an oral anticoagulant medication. Billing teams must be aware that affected lot numbers should not be dispensed, and claims for recalled lots may be subject to denial or adjustment by the plan.
Action Required
Immediately: Billing and pharmacy teams must identify patients who received Dabigatran from the 10 recalled lots. Coordinate with the dispensing pharmacy and clinical providers to determine if affected patients need medication replacement or clinical follow-up. Do not process claims for recalled lot numbers without plan approval. Flag any claims already submitted for recalled lots and contact UPM Health Plan at the link provided for guidance on claim adjustment or reprocessing. Verify lot numbers against the recall list before authorizing refills.